Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Celgene Gets Another Myeloma CAR-T Accepted Onto EMA’s PRIME

Executive Summary

Bristol-Myers Squibb’s newly acquired company Celgene is one of two drug sponsors that this month made it onto the European Medicines Agency’s priority medicines scheme. The other is Achillion Pharmaceuticals, which is developing a treatment for paroxysmal nocturnal hemoglobinuria.

You may also be interested in...



With Celgene Acquisition Closed, Bristol Faces Major Milestones

Bristol bought Celgene following multiple pipeline setbacks, but the biotech giant made positive progress recently that the big pharma will be expected to continue. 

Myeloma BCMA Therapy In Spotlight: EMA Considers Fast Tracking GSK Filing

The European Medicines Agency is this week deciding whether GlaxoSmithKline’s planned EU marketing application for its BCMA-targeting therapy merits an accelerated assessment.

Alexion Buys A Complementary Business With Achillion

The company agreed to pay $930m up front to acquire Achillion, which has two drugs in Phase II development for complement alternative pathway-mediated rare diseases.

Topics

Related Companies

UsernamePublicRestriction

Register

PS141250

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel